![]() |
|
|
Vol. 54, Issue 6, 1036-1045, December 1998
Department of Pharmaceutical Sciences, University of Padova, 35131 Padova, Italy (C.S., L.B., S.M., G.Z., M.P.),
INSERM U124 and
Laboratoire de Pharmacologie Antitumorale Moléculaire, Centre
Oscar Lambret, 59045 Lille, France (C.B.),
Boehringer Mannheim Italia,
20052 Monza, Italy (E.M.), and
Division of Experimental Oncology B,
Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan,
Italy (G.C.)
To elucidate structure-activity relationships for drugs that are able
to poison or inhibit topoisomerase II, we investigated the
thermodynamics and stereochemistry of the DNA binding of a number of
anthracene derivatives bearing one or two
4,5-dihydro-1H-imidazol-2-yl-hydrazone side chains
(characteristic of bisantrene) at different positions of the planar
aromatic system. An aza-bioisostere, which can be considered a
bisantrene-amsacrine hybrid, was also tested. The affinity for nucleic
acids in different sequence contexts was evaluated by spectroscopic
techniques, using various experimental conditions. DNA-melting and
DNase I footprinting experiments were also performed. The location and
number of the otherwise identical side chains dramatically affected the
affinity of the test compounds for the nucleic acid. In addition, the
new compounds exhibited different DNA sequence preferences, depending
on the locations of the dihydroimidazolyl-hydrazone groups, which
indicates a major role for the side-chain position in generating
specific contacts with the nucleic acid. Molecular modeling studies of
the intercalative binding of the 1- or 9-substituted isomers to DNA
fully supported the experimental data, because a substantially more
favorable recognition of A-T steps, compared with G-C steps, was
found for the 9-substituted derivative, whereas a much closer energy
balance was found for the 1-substituted isomer. These results compare well with the alteration of base specificity found for the
topoisomerase II-mediated DNA cleavage stimulated by the isomeric
drugs. Therefore, DNA-binding specificity appears to represent an
important determinant for the recognition of the topoisomerase-DNA
cleavable complex by the drug, at least for poisons belonging to the
amsacrine-bisantrene family.
This article has been cited by other articles:
![]() |
D. Strumberg, J. L. Nitiss, J. Dong, K. W. Kohn, and Y. Pommier Molecular Analysis of Yeast and Human Type II Topoisomerases. ENZYME-DNA AND DRUG INTERACTIONS J. Biol. Chem., October 1, 1999; 274(40): 28246 - 28255. [Abstract] [Full Text] [PDF] |
||||